Clinical Trial: A Clinical Trial Evaluating the Tolerability, Safety, and Preliminary Efficacy of NRG-103 Injection in Patients With Recurrent or Progressive High-grade Glioma

U.S., July 18 -- ClinicalTrials.gov registry received information related to the study (NCT07710690) titled 'A Clinical Trial Evaluating the Tolerability, Safety, and Preliminary Efficacy of NRG-103 Injection in Patients With Recurrent or Progressive High-grade Glioma' on July 13.

Brief Summary: The primary objective of this study is to determine the safe dose range of NRG-103 in patients and to recommend the dosage for subsequent treatment, while also evaluating the preliminary efficacy and tolerability of the product.

Study Start Date: July 09

Study Type: INTERVENTIONAL

Condition: HGG High Grade Glioma (III or IV) High Grade Glioma

Intervention: DRUG: NRG-103

NRG-103

Recruitment Status: RECRUITING

Sponsor: Neuregen Therapeutics ...